Cancer Res Treat.  2019 Jan;51(1):1-11. 10.4143/crt.2018.028.

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial

Affiliations
  • 1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac
  • 2Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea.
  • 3Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea.
  • 4Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
  • 5Division of Hemato-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.
  • 6Division of HematologyOncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • 7Division of Hematology-Oncology, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
  • 8Division of HematoOncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea.
  • 9Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • 10Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • 11Song-Dang Institutefor Cancer Research, Yonsei University College of Medicine, Seoul, Korea.
  • 12Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
MATERIALS AND METHODS
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2/day on days 1-14 plus docetaxel 35 mg/m2on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2/day on days 1-14 plus cisplatin 60 mg/m2on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
RESULTS
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
CONCLUSION
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Keyword

Stomach neoplasms; Stage III; S-1 based doublet; Docetaxel; Cisplatin; Adjuvant chemotherapy

MeSH Terms

Anemia
Capecitabine
Chemotherapy, Adjuvant*
Cisplatin
Disease-Free Survival
Follow-Up Studies
Gastrectomy
Hand-Foot Syndrome
Humans
Korea
Lymph Node Excision
Mucositis
Neutropenia
Stomach Neoplasms*
Capecitabine
Cisplatin
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error